As Washington Waits On Pricing Proposals, A Call For A Reset In R&D Debate
Executive Summary
Policymakers should clarify link between high drug prices and innovation and figure out how to “rebalance” high prices with non-price innovation incentives before proceeding with policies aimed directly at lowering prices, Conti and David propose in the Health Affairs Blog.
You may also be interested in...
Beyond ICER: Arnold Foundation Wants To Dig Deeper On R&D And Pricing
Arnold Foundation VP Mark Miller explains how research into “what it costs to bring a drug to market” could supplement existing efforts to determine how prescription drug prices line up with value.
US FDA, USP Cooperate On Small Molecule Drug Monograph Updates To Speed ANDAs
Generic applicants can request monograph changes while FDA assessment is ongoing.
A Case For List Price Cuts? Study Highlights Reduced 340B Liability For Hep C Drugs
Lower list prices for Epclusa, Harvoni, and Zepatier might actually boost revenue by reducing 340B discounts, but rebate-eschewing dynamic may not expand beyond them because of different exposures to 340B in other classes – and the pending HHS rebate rule.